Wang et al. demonstrated that caspase-1 was downregulated in NSCLC tumor tissues and found that simvastatin (SIM), an anti-hyperlipidaemia drug, inhibits the growth of NSCLC by activating caspase-1-dependent pyroptosis in xenograft mouse models and in A549 and H1299 lung cancer cells [67]. This evidence concerns the gene CASP1 and hyperlipidemia.